EU309
/ Eutilex
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
June 10, 2022
Eutilex to start Korea’s 1st clinical trial for CAR-T in treating solid cancers
(Korea Biomedical Review)
- "Eutilex said it would begin clinical trials for a CAR-T treatment to treat solid cancer for the first time in Korea. The company plans to submit an investigational new drug application (IND) for its CAR-T treatment pipeline in the second half of this year and has already secured non-clinical efficacy data. EU307 (GPC3-IL18 CAR-T treatment), the candidate set for IND application, targets GPC3, a substance overexpressed in 70-80 percent of liver cancer patients among solid cancers....'In addition to EU307, Eutilex will also apply for EU301 (MVR CAR-T treatment) targeting HLA-DR and apply a patent for EU309, a treatment targeting brain tumors'..."
New trial • Patent • Brain Cancer • CNS Tumor • Gastrointestinal Cancer • Liver Cancer • Oncology • Solid Tumor
1 to 1
Of
1
Go to page
1